Welcome to Markets Desk, let's get you caught up.
IBM is under the microscope after cutting its revenue guidance, and analysts are putting the company on notice. The tech giant maintained its free cash flow target, expecting roughly one billion dollars in growth through two thousand twenty six, but Wall Street is clear — the credibility gap needs to close with execution, not promises.
Shifting to biotech, BeOne Medicines is making a significant bet on American manufacturing, announcing a three hundred million dollar expansion at its New Jersey campus that brings its total U.S. investment north of one billion dollars. It's a notable commitment to domestic production at a moment when supply chain resilience is very much on the industry's mind.
And staying with pharmaceuticals, the FDA is weighing whether seven peptides — including BPC-one fifty seven and TB-five hundred — can be legally compounded for broader use. These compounds have circulated in wellness and performance communities for years, largely in a gray market. A regulatory green light would reshape access significantly and open a meaningful commercial pathway for compounding pharmacies.
That's the tape. Markets Desk, signing off the floor.
